Andreas Balser

Andreas Balser serves as CTO at Dopavision. Dopavision operates in the medical devices sector with approximately 17.0 employees. The company is headquartered in Munich, Bavaria. Dopavision generates annual revenue of 2000000.0. To date, Dopavision has raised 17086956.0 in total funding, with the most recent round being Series A.

Industry & Role Insights

• • MessageCEO tracks 1,888 executives in the medical devices sector.
• • 1,671 executive contacts are available in Bavaria.
• • Our database includes 201,465 c suite-level executives.

Outlook Nginx WordPress.org Mobile Friendly Google Font API Google Tag Manager Android Remote Circle Basis AI

medical device myopia ophthalmology nearsightedness digital health optometry myopiax selective ocular light stimulation non-invasive therapy nearsightedness treatment digital therapy child-friendly virtual reality therapy eye care technology dopamine modulation clinical trial healthcare solutions interactive digital experience myopia control retina health visual function patient safety interactive content gamified treatment child vision medical research biopharmaceuticals health technologies progressive myopia light-based treatment eye growth regulation therapeutic approach photosensitive cells medical standards compliance user experience home treatment child health education games treatment adherence clinical investigation sight rehabilitation ocular health user engagement medical innovation healthcare professionals data monitoring user compliance pharmaceutical development children's eye health global health initiative hospital & health care health wellness & fitness information technology & services ux

YM

Yahia Megahed CEO at 360Imaging

HA

Hugo Azevedo Chief Technology Officer at 3B Scientific

MP

Marie-Laure Pochon CEO & President at 3DISC

KD

Khanh Duy Co-CEO at 3D-Side

K

Khanh Co-CEO at 3D-Side

Outreach Guidance — medical devices Sector

Executives like Andreas Balser in the medical devices sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at Dopavision.

Andreas Balser's Position in the MessageCEO Database

• •Andreas Balser is 1 of 1 verified executive contact we track at Dopavision.
• •1,787 verified executive contacts in medical devices are in the MessageCEO database.
• •1,664 verified executive contacts in Bavaria are in the database.
• •4 verified contacts work at medical devices companies in the 17.0 employee range (same size as Dopavision).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated October 2026.

How do I reach Andreas Balser directly?

Andreas Balser's verified email address is available to MessageCEO Pro subscribers. They currently serve as CTO at Dopavision. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Andreas Balser work for?

Andreas Balser is CTO at Dopavision, a company in the medical devices sector with 17.0 employees. The company is based in Munich, Bavaria.

Can I pitch or sell to Andreas Balser?

As CTO at Dopavision, Andreas Balser is a key decision-maker in the medical devices sector. MessageCEO Pro gives you verified email to reach Andreas Balser directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Andreas Balser in?

Andreas Balser works in the medical devices industry as CTO at Dopavision. MessageCEO provides verified contact information for executives across all major industries.

Is Andreas Balser's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Andreas Balser's profile is kept up-to-date with the latest available information.

Last updated: October 7, 2026